secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0000059478-22-000248
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q3 2022: revenue up 2% to $6.94B, reported EPS $1.61 (+32%), Mounjaro launch strong
--------------------------------------------------------------------------------

- Revenue $6,941.6M (+2% reported, +7% constant currency); total volume +14%.
- Reported EPS $1.61 (+32%); non-GAAP EPS $1.98 (+12%); both inclusive of $0.06 acquired IPR&D charges.
- Mounjaro U.S. revenue $97.3M in first full quarter; plus $86.0M from Japan collaboration agreement.
- Key growth products (Verzenio, Trulicity, Mounjaro, etc.) grew 19% and represented 70% of revenue (ex-COVID antibodies).
- 2022 EPS guidance updated: reported $6.50-$6.65, non-GAAP $7.70-$7.85, inclusive of $0.67 charges.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947822000248/0000059478-22-000248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947822000248/lly-20221101.htm
  HTML page:      https://secwatch.observer/filing/0000059478-22-000248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer